in the absence of a submission from the holder of the marketing authorisation:
raltegravir (Isentress®) is not recommended for use within NHSScotland.
Indication under review: in combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice135KB (PDF)
- Medicine name:
- raltegravir (Isentress)
- SMC ID:
- in combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.
- Pharmaceutical company
- BNF chapter
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 09 July 2018